Suchergebnisse - "Shoji, Hirokazu"

PubPharm (180)

1

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer : A phase II trial (HYBRID)

enthalten in: Cancer medicine | 2024

von Arai, H. | Tsuda, T. | Sunakawa, Y. | +13

2

Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab

enthalten in: International journal of clinical oncology | 2024

von Wakatsuki, T. | Ishizuka, N. | Hironaka, S. | +11

3

Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin

enthalten in: In vivo (Athens, Greece) | 2024

von Yada, M. | Yamamoto, S. | Honma, Y. | +7

4

A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer : WJOG 11018G

enthalten in: Targeted oncology | 2024

von Matsumoto, T. | Yamamoto, Y. | Kotaka, M. | +19

5

Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma

enthalten in: Esophagus : official journal of the Japan Esophageal Society | 2024

von Hirose, T. | Yamamoto, S. | Honma, Y. | +11

6

A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G

enthalten in: Targeted oncology | 2024

von Matsumoto, T. | Yamamoto, Y. | Kotaka, M. | +19

7

CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer

enthalten in: American journal of cancer research | 2024

von Oshima, K. | Shoji, H. | Boku, N. | +5

8

Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer : a multicenter, open-label, expanded-access study

enthalten in: International journal of clinical oncology | 2024

von Shitara, K. | Yamaguchi, K. | Muro, K. | +10

9

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer : A phase II trial ( HYBRID)

enthalten in: Cancer Medicine | 2024

von Arai, H. | Tsuda, T. | Sunakawa, Y. | +13

10

Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study

enthalten in: International journal of clinical oncology | 2023

von Shitara, K. | Yamaguchi, K. | Muro, K. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]